Published online before print September 18, 2008, doi: 10.1161/CIRCRESAHA.108.177683
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2008 American Heart Association, Inc.
Cellular Biology |
Acceleration of Crossbridge Kinetics by Protein Kinase A Phosphorylation of Cardiac Myosin Binding Protein C Modulates Cardiac Function
From the Department of Physiology, University of Wisconsin School of Medicine and Public Health, Madison.
Correspondence to Richard L. Moss, PhD, Professor and Chair, Department of Physiology, University of Wisconsin School of Medicine and Public Health, Room 123 SMI, 1300 University Ave, Madison, WI 53706. E-mail rlmoss{at}physiology.wisc.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Normal cardiac function requires dynamic modulation of contraction. β1-Adrenergic–induced protein kinase (PK)A phosphorylation of cardiac myosin binding protein (cMyBP)-C may regulate crossbridge kinetics to modulate contraction. We tested this idea with mechanical measurements and echocardiography in a mouse model lacking 3 PKA sites on cMyBP-C, ie, cMyBP-C(t3SA). We developed the model by transgenic expression of mutant cMyBP-C with Ser-to-Ala mutations on the cMyBP-C knockout background. Western blots, immunofluorescence, and in vitro phosphorylation combined to show that non–PKA-phosphorylatable cMyBP-C expressed at 74% compared to normal wild-type (WT) and was correctly positioned in the sarcomeres. Similar expression of WT cMyBP-C at 72% served as control, ie, cMyBP-C(tWT). Skinned myocardium responded to stretch with an immediate increase in force, followed by a transient relaxation of force and finally a delayed development of force, ie, stretch activation. The rate constants of relaxation, krel (s-1), and delayed force development, kdf (s-1), in the stretch activation response are indicators of crossbridge cycling kinetics. cMyBP-C(t3SA) myocardium had baseline krel and kdf similar to WT myocardium, but, unlike WT, krel and kdf were not accelerated by PKA treatment. Reduced dobutamine augmentation of systolic function in cMyBP-C(t3SA) hearts during echocardiography corroborated the stretch activation findings. Furthermore, cMyBP-C(t3SA) hearts exhibited basal echocardiographic findings of systolic dysfunction, diastolic dysfunction, and hypertrophy. Conversely, cMyBP-C(tWT) hearts performed similar to WT. Thus, PKA phosphorylation of cMyBP-C accelerates crossbridge kinetics and loss of this regulation leads to cardiac dysfunction.
Key Words: cMyBP-C • phosphorylation • contraction kinetics
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The strength and kinetics of cardiac contraction vary on a beat-to-beat basis as a way to match cardiac output to the circulatory demands of the body. Reduced capacity to modulate contraction has long been recognized as a key feature of dysfunction in heart failure1 and more recently in hypertrophic cardiomyopathy (HCM).2 This study explores the possibility that phosphorylation of cardiac myosin binding protein (cMyBP)-C modulates contraction in skinned and living myocardium.
MyBP-C is a component of the thick filament in striated muscle3 and is evident as 7 to 9 bands at 43-nm intervals4 within the center of each half-thick filament in the A-band. Its location at every third crossbridge crown, ie, every 42.9 nm5 suggests that cMyBP-C has a regulatory role with respect to thick filament activity. Unlike the skeletal muscle isoform, cMyBP-C is readily phosphorylated by protein kinase (PK)A,6,7 calcium calmodulin kinase (CaMK)II,6,7 and PKC.8,9 Phosphorylation of cMyBP-C may promote actin–myosin interactions by either relieving a structural constraint on myosin to allow closer proximity with actin10,11 or reducing the binding of cMyBP-C to the S2 domain of myosin to allow greater flexibility of the rod that links the myosin head to the thick filament.12,13 Thus, phosphorylation of cMyBP-C may affect cardiac function by regulating crossbridge kinetics.
Evidence suggests that cMyBP-C and its phosphorylation status are critical to regulation of cardiac function. For example, mutations of cMyBP-C comprise the most prevalent cause of familial hypertrophic cardiomyopathy.14,15 Phosphorylation of cMyBP-C is reduced in human heart failure16 and atrial fibrillation.17 In animal models, increased cMyBP-C phosphorylation has been associated with reduced infarct size,18 whereas decreased phosphorylation is associated with dysfunction in failure19 and with either dysfunction20 or preservation21 of function in ischemia.
A previously developed cMyBP-C knockout (KO)22 mouse provided initial indications concerning the roles of cMyBP-C phosphorylation in the heart. For example, skinned myocardium from cMyBP-C KO hearts exhibits constitutively accelerated crossbridge kinetics similar to wild-type (WT) hearts after treatment with PKA,23 suggesting that phosphorylation of cMyBP-C accelerates crossbridge kinetics in response to β1-adrenergic stimulation. Hearts from cMyBP-C KO mice exhibit hypertrophy, diastolic dysfunction, and systolic dysfunction.22 In contrast, PKA accelerates crossbridge kinetics in skinned myocardium from mouse hearts expressing mutant non–PKA-phosphorylatable cardiac troponin (cTn)I, ie, cTnIala2.24 Unlike cMyBP-C KO hearts, cTnIala2 hearts exhibit normal function.24 These results narrow the mechanism of acceleration of crossbridge kinetics by PKA phosphorylation to cMyBP-C and suggest that cMyBP-C phosphorylation is important for normal cardiac function.
We hypothesized that PKA phosphorylation of cMyBP-C in response to β1-adrenergic stimulation accelerates crossbridge kinetics in vivo, whereas the loss of this regulatory mechanism leads to cardiac dysfunction. To test this idea, we transgenically expressed constitutively non–PKA-phosphorylatable cMyBP-C on the cMyBP-C KO22 background. We found that skinned myocardium from these hearts no longer exhibits acceleration of contraction kinetics in response to treatment with PKA. Furthermore, hearts with non–PKA-phosphorylatable cMyBP-C exhibit hypertrophy, diastolic dysfunction, systolic dysfunction, and reduced contractile reserve.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Mouse Lines
N-terminal myc-tagged WT or non–PKA-phosphorylatable cMyBP-C was expressed on the cMyBP-C–null background. Gautel et al25 previously identified three PKA phosphorylation sites in human cMyBP-C at Ser275, Ser284, and Ser304; the homologous sites in mouse cMyBP-C are Ser273, Ser282, and Ser302. Here, all 3 residues were mutated to alanine (Figure 1A), and the
-myosin heavy chain promoter was used to promote expression of the mutant transgene in the FVB/N mouse strain. FVB/N mice expressing the transgene were bred with the previously generated cMyBP-C KO mouse (E129X1 strain)22 to ensure expression of the exogenous transgene without competition from native cMyBP-C. WT cMyBP-C was also expressed in cMyBP-C KO mice to serve as a control. t3SA denotes transgenic expression of the Ser-to-Ala mutant cMyBP-C and tWT denotes transgenic expression of WT cMyBP-C. The protocols for care and use of animals were approved by the Animal Care and Use Committee of the University of Wisconsin School of Medicine and Public Health.
|
Myofibril Preparation
Myofibril homogenates were prepared from hearts for subsequent analysis using electrophoresis, Western blotting, immunofluorescence, and in vitro PKA phosphorylation (see the online data supplement, available at http://circres.ahajournals.org).
Western Blots
Western blots were used to determine total expression of transgenes using a rabbit polyclonal anti–cMyBP-C antibody22 at a dilution of 1:10 000 and a mouse monoclonal anti-myc (Upstate 05-419 clone 9E10) antibody at 1:250 dilution (see the online data supplement).
Immunofluorescence
Immunofluorescence labeling of myofibrils was used to verify incorporation of transgenic cMyBP-C into the thick filament. Rabbit anti–cMyBP-C polyclonal antibody22 at 1:250 dilution was paired with Alexa-Fluor647 (Molecular Probes) goat anti-rabbit secondary antibody at 1:250. Mouse monoclonal anti-myc (Upstate 05-419 clone 9E10) antibody at 1:25 was paired with Alexa-Fluor488 (Molecular Probes) goat anti-mouse secondary antibody at 1:250. (See the online data supplement.)
PKA Phosphorylation of Myofibrillar Proteins
Exogenous catalytic subunit of PKA (Sigma P2645) was used to phosphorylate cMyBP-C and cTnI in isolated myofibrils and in the preparations used for mechanical measurements (see the online data supplement). The ratio of enzyme to total myofibrillar protein (wt/wt) was 0.05 (1 U/µL PKA according to Sigma specifications for activity).
Comparison of Phosphorylation Levels
For each phosphorylation reaction, gel (10% polyacrylamide) lanes were loaded with different volumes of myofibrils at known concentrations. Pro-Q Diamond (Molecular Probes, phosphoprotein stain) and Sypro-Ruby (Molecular Probes, total protein stain) were used to compare phosphorylation levels of cMyBP-C and cTnI. Slopes of Pro-Q intensity versus protein load and slopes of Sypro-Ruby intensity versus protein load were calculated for each experiment. Double ratio "PL(experiment/WTbaseline)" of Pro-Q/protein slope to Sypro/Protein slope of an experiment in comparison to WT baseline provided a semiquantitative assessment (see the online data supplement). 
|
|
Stretch Activation and Force Versus pCa Measurements
Stretch activation was assessed in skinned myocardium23 with or without exogenous PKA (Sigma P2645) to quantify the effects of PKA phosphorylation of regulatory proteins on crossbridge kinetics. This was done by setting pCa (pCa=–log10[Ca2+]) to achieve half-maximal force, setting sarcomere length at 2.1 µm, and applying a rapid stretch of 1% of fiber length (see the online data supplement). Force values were measured at various pCa to characterize force–pCa relationships.26
Heart and Body Weight Determinations
Heart weight/body weight ratios were determined as an indicator of cardiac hypertrophy. Once anesthetized, mice (2 to 6 months of age) were weighed to determine total body weight. Hearts were then removed, all major vessels and connective tissues were dissected away, and the heart including the atrial appendage was carefully blotted and weighed.
Echocardiography
Echocardiography was done using a Visualsonics Vevo 770 system with a 30-MHz probe to record intact in vivo cardiac structure and function using M-mode, B-mode, blood flow Doppler, tissue Doppler, and ECG-gated reconstruction of left ventricle changes during a cardiac cycle (EKV mode). Dobutamine (10 µg/g) was administered by IP injection to elicit a maximum β1 response that was sustained for 15 minutes27 to maximize in vivo PKA phosphorylation. Postdobutamine imaging was initiated 8 minutes after IP injection. All measured parameters were averages from a minimum of 3 cardiac cycles (see the online data supplement).
Statistical Analysis
Statistical analyses were done using SPSS statistical analysis software with significance set at P<0.05. ANOVA with post hoc Tukey honestly significant difference tests were used to determine significant differences between specific groups for comparisons involving more than 2 groups. Paired t tests were used only to determine significant differences before and after treatment within a group. Unless otherwise noted, all data are presented as means±SEM.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
cMyBP-C Transgene Expression
Double positive staining of anti-cMyBP-C and anti-myc Western blots verified expression of transgenes that were introduced into the KO mice (Figure 1B). WT myocardium showed positive staining for anti–cMyBP-C but not anti-myc, whereas KO showed no positive staining. The mouse lines 309 (t3SA) and 519 (tWT) chosen for these experiments had closely matched expression of transgenic cMyBP-C, ie, 74%±2 and 72%±3 of control, respectively (Figure 1C).
Incorporation of cMyBP-C
The expressed cMyBP-C appeared to be appropriately positioned in both cMyBP-C(t3SA) and cMyBP-C(tWT) myocardium. Immunofluorescent labeling of myofibrils with anti–cMyBP-C/Alexa-Fluor647 showed A-band doublets containing cMyBP-C in WT, cMyBP-C(tWT), and cMyBP-C(t3SA) myocardium but not in KO myocardium (Figure 2A through 2D). Anti-myc/Alexa-Fluor488 showed the same doublets in cMyBP-C(tWT) and cMyBP-C(t3SA) but not in WT or KO myocardium (Figure 2A, 2C, and 2D). Overlay of anti–cMyBP-C and anti-myc fluorescence images yielded matches for both cMyBP-C(tWT) and cMyBP-C(t3SA) myocardium (Figure 2C and 2D). Anti-myc/Alexa-Fluor488 in WT myocardium showed only low-intensity nonspecific fluorescence at the Z-line (Figure 2A). Anti-cMyBP-C/Alexa-Fluor647 labeling of KO myofibrils exhibited only nonspecific low-intensity background fluorescence at the same level as the secondary Alexa-Fluor647 antibody alone (Figure 2B).
|
PKA Phosphorylation of cMyBP-C and cTnI
ProQ Diamond phosphoprotein staining showed that PKA did not phosphorylate the mutant cMyBP-C in cMyBP-C(t3SA) myocardium but phosphorylated cMyBP-C in both cMyBP-C(tWT) and WT myocardium (Figure 3 and Table 1). Conversely, PKA treatment increased phosphorylation of cTnI in all lines to essentially equal levels (Figure 3). The similar PKA phosphorylation of cTnI in all mouse lines showed that PKA activity was similar between experiments; consequently, the lack of phosphorylation of mutant cMyBP-C could not be attributed to low PKA activity.
|
|
Stretch Activation of Myocardium
Stretch activation at 50% maximal force in cMyBP-C(t3SA) skinned myocardium differed from that in both WT and cMyBP-C(tWT) myocardium (Figure 4A and 4B and Table 1) but only after PKA treatment. Before PKA treatment, cMyBP-C(t3SA) myocardium exhibited similar rates of force decay (krel) and delayed force development (kdf) as in WT and cMyBP-C(tWT) myocardium (Table 1). Unlike WT and cMyBP-C(tWT), PKA treatment had no effect on either phase of the stretch activation response in cMyBP-C(t3SA) in that the rate constants krel and kdf were unchanged after PKA treatment. Thus, the acceleration of contraction kinetics in WT myocardium requires phosphorylation of cMyBP-C but does not involve cTnI.
|
As shown in the recording in Figure 4C, cMyBP-C(t3SA) myocardium exhibited slower rates of force decay and delayed force development in comparison to KO myocardium both before and after PKA treatment (Table 1). As previously reported,23 contraction kinetics in KO were unaffected by PKA (Table 1).
cMyBP-C(t3SA) exhibited a small increase in β myosin heavy chain (βMHC) content, ie, <10% of total MHC, which is significantly less than the 13% to 19% βMHC in KO myocardium (Figure I in the online data supplement). All 4 lines of mice showed similar levels of titin phosphorylation (supplemental Figure II). Thus, neither βMHC expression nor titin phosphorylation can account for the observed differences in kinetics.
Force–pCa Relationships
Myocardium from all 4 lines exhibited similar steady-state force responses to variations in activating calcium, both at baseline and following treatment with PKA (Table 1). Figure 4D shows force–pCa relationships for cMyBP-C(t3SA) and cMyBP-C(tWT) myocardium. PKA treatment decreased pCa50 within each line; however, there were no differences between the lines either at baseline or following PKA treatment (see supplemental Table II). Thus, the PKA-induced decrease in Ca2+ sensitivity of force does not involve phosphorylation of cMyBP-C but instead is attributable to phosphorylation of cTnI.28
Heart Weight/Body Weight Ratio
Both cMyBP-C(t3SA) and cMyBP-C(tWT) mice exhibited a generally normal physical appearance and no evidence of early mortality. However, cMyBP-C(t3SA) and KO mice had significantly increased heart weight/body weight ratios compared to ratios for WT and cMyBP-C(tWT) mice, indicating cardiac hypertrophy (Table 2).
|
Echocardiography
Echocardiography demonstrated similar hypertrophy and severe global dysfunction in cMyBP-C(t3SA) and KO hearts (Table 2 and Figure 5). Dramatically increased posterior wall thickness during diastole with normal left ventricular (LV) inner diameter indicated hypertrophy. Increased IVRT indicates a longer time for LV relaxation before the start of filling during diastole, implying impaired relaxation. The ratio of the blood flow Doppler peak (E) at mitral inflow to the tissue movement Doppler peak (e’) at the lateral mitral annulus (E/e')29 provided another index of diastolic function. The increased E/e' ratio indicated that the rates of myocardial relaxation were slowed, ie, there was diastolic dysfunction in these hearts. Reduced fractional shortening (FS) under basal conditions indicated systolic dysfunction in both cMyBP-C(t3SA) and KO hearts.
|
Dobutamine treatment showed that cMyBP-C(t3SA) and KO hearts have different levels of reduced contractile reserve (Table 2). Dobutamine increased FS and EF in WT and cMyBP-C(tWT) hearts to the same maximal level. However, dobutamine increased FS and EF of cMyBP-C(t3SA) hearts to lower levels than either WT or cMyBP-C(tWT) hearts, which indicates reduced contractile reserve. KO hearts exhibited smaller increases in both EF and FS than did cMyBP-C(t3SA) hearts, indicating that KO hearts had the lowest contractile reserve of all the lines, ie, the rank order of contractile reserve was WT=cMyBP-C(tWT)>cMyBP-C(t3SA)>KO.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We have transgenically expressed non–PKA-phosphorylatable cMyBP-C on a cMyBP-C KO background to study the functional effects of PKA phosphorylation of cMyBP-C in living myocardium. Stretch activation studies on skinned myocardium from cMyBP-C(t3SA) mice demonstrated the loss of PKA mediated acceleration of contraction kinetics. In vivo echocardiography showed hypertrophy, diastolic dysfunction, systolic dysfunction, and reduced dobutamine augmentation of systolic function in cMyBP-C(t3SA) hearts. Thus, our data indicated that PKA phosphorylation of cMyBP-C in response to β1-adrenergic stimulation accelerates crossbridge kinetics, and loss of this regulatory mechanism contributes to cardiac dysfunction.
Stretch activation measurements showed that PKA phosphorylation of cMyBP-C accelerated crossbridge kinetics, a phenomenon that does not involve cTnI. After an initial elastic response to stretch, the concurrent processes of crossbridge detachment, crossbridge attachment, and reversal of power stroke all contribute to the phases of force decay and delayed force development, with detachment and attachment comprising the dominant contributions.30–32 The rate constants of force decay (krel) and delayed force development (kdf) manifest crossbridge turnover kinetics. WT and cMyBP-C(tWT) myocardium showed increased krel and kdf following PKA treatment, with corresponding increases in phosphorylation of cMyBP-C. In contrast, cMyBP-C(t3SA) myocardium did not show any changes in krel or kdf in response to PKA treatment because of the failure of PKA to phosphorylate the mutant cMyBP-C.
Previous work by Stelzer et al24 showed that the PKA acceleration of kdf was absent in cMyBP-C–null myocardium, but baseline kinetics in null myocardium were accelerated to levels observed in WT myocardium following PKA treatment. This left open the possibility that crossbridge cycling kinetics were saturated in null myocardium, such that if cTnI phosphorylation had an effect on kinetics, it would not be observed in this preparation. The present results eliminate this possibility because the baseline (pre-PKA) kinetics of cMyBP-C(t3SA) myocardium were similar to WT and cMyBP-C(tWT) myocardium, and yet cMyBP-C(t3SA) myocardium exhibited no change in kdf on treatment with PKA.
Echocardiography during dobutamine augmentation provided evidence of enhancement of global function attributable to PKA phosphorylation of cMyBP-C. Dobutamine stimulated β1-adrenergic activity in vivo to cause PKA phosphorylation of contractile proteins including cMyBP-C. Dobutamine also increases the amplitude and accelerates the kinetics of calcium transients.33 In this study, dobutamine increased EF and FS of cMyBP-C(t3SA) hearts to a lesser extent than in WT or cMyBP-C(tWT) hearts. Dobutamine augmentation of systolic function in cMyBP-C(t3SA) hearts can be attributed to enhanced calcium transients, whereas the lesser effects of dobutamine on cMyBP-C(t3SA) can be attributed to the absence of acceleration of crossbridge kinetics resulting from lack of PKA phosphorylation of cMyBP-C.
Considerable evidence supports the idea that the global cardiac dysfunction observed in cMyBP-C(t3SA) hearts is related to the inability to modulate crossbridge kinetics as a means to vary cardiac performance. For example, the nonselective β-blocker propranolol reduces phosphorylation of cMyBP-C in rats34 and depresses the positive force frequency response of intact papillary muscle from mice.35 In cMyBP-C(t3SA) myocardium, the inability to accelerate crossbridge kinetics with β1-adrenergic stimulation could provide the stimulus for compensatory hypertrophy and further dysfunction. Work by Perrino et al36 showing that either chronic or intermittent pressure overload can cause hypertrophy and dysfunction in mice is consistent with this hypothesis. Increased LV thickness with normal LV inner cavity dimension seen on echocardiography of cMyBP-C(t3SA) mice and the increased heart weight to body weight ratios provided evidence for hypertrophy. Increased IVRT and E/e' ratio indicated diastolic dysfunction, whereas reduced FS indicated systolic dysfunction. Thus, cMyBP-C(t3SA) hearts showed global dysfunction that is attributed directly or via compensatory hypertrophy to the inability to accelerate crossbridge kinetics in response to β-adrenergic agonists.
PKA also phosphorylates cTnI in response to β1 stimulation, and previous studies suggest that phosphorylation of cTnI plays a role in PKA acceleration of crossbridge kinetics37; however, our results cannot be attributed to PKA phosphorylation of cTnI, because PKA treatment phosphorylated cTnI in cMyBP-C(t3SA) and WT myocardium to similar levels. Our observation that PKA treatment caused a similar decrease in calcium sensitivity of force in both cMyBP-C(t3SA) and WT myocardium provided functional verification that PKA similarly phosphorylated cTnI in the 2 mouse lines. In a separate study, PKA treatment accelerated crossbridge kinetics in myocardium expressing native cMyBP-C and exclusively non–PKA-phosphorylatable cTnI; however, PKA did not accelerate crossbridge kinetics in cMyBP-C–null myocardium, despite similar increases in the level of phosphorylation of TnI.24 Thus, in the present study, the acceleration of crossbridge kinetics attributable to PKA treatment of skinned myocardium is mediated by phosphorylation of cMyBP-C, whereas the decrease in Ca2+ sensitivity of force is caused by phosphorylation of cTnI.
Our results do not eliminate the possibility that cMyBP-C phosphorylation would affect Ca2+ sensitivity of force at a sarcomere length different from that used here, ie, 2.1 µm, because Cazorla et al38 reported length-dependent differences in the effects of PKA on Ca2+ sensitivity in WT and null myocardium. Although both types of myocardium exhibited a decrease in Ca2+ sensitivity at an sarcomere length of 1.9 µm,38 only WT exhibited this decrease at 2.3 µm,38 leaving open the possibility that cMyBP-C phosphorylation modulates length-dependence of contraction.
Alterations in myofilament responsiveness to calcium during the cardiac cycle may explain why different changes in kinetics in cMyBP-C(t3SA) and KO myocardium led to similar cardiac dysfunction. Initial calcium binding to troponin converts the thin filament from a "blocked" state to a "closed" state in which crossbridges are more likely to bind.39 Subsequent crossbridge attachment with the ensuing transition from weakly to strongly bound states further activates the thin filament to an "open" state and cooperatively promotes further crossbridge attachment.39–41 Cooperative binding of strongly bound crossbridges maintains the thin filaments in the open state, which allows continued crossbridge attachment and results in a continued increase in force during the initial decay in calcium.35,42,43 The constitutively slower kinetics of cMyBP-C(t3SA) myocardium would reduce the number of crossbridges that bind during a twitch in response to the rise in calcium and resulting from cooperative recruitment. In contrast, the constitutively accelerated kinetics of KO myocardium would reduce the dwell time of strongly bound crossbridges, which would reduce the cooperative recruitment of crossbridges during the initial decline in Ca2+ during the twitch. The shortened ejection time in KO hearts is consistent with this idea.44 Thus, the slowed kinetics of crossbridge turnover in cMyBPC(t3SA) myocardium would reduce force generated per unit calcium change during a twitch, whereas the faster kinetics of KO myocardium would abbreviate force generation once Ca2+ begins to decline, both of which would decrease peak myocardial force and lead to pump dysfunction. Conversely, KO myocytes demonstrated prolonged calcium transient decay45; thus, slowed calcium handling likely caused impaired relaxation that was seen by echocardiography of KO hearts.
There are other potential phosphorylation sites on cMyBP-C, but these were not changed by the mutations and did not affect our findings. Yuan et al21 recently reported additional phosphorylation sites in canine cMyBP-C with murine homologs at Ser284 and Ser307. Basal phosphorylation of these additional sites in vivo could explain the weakly positive ProQ-Diamond staining of the mutant cMyBP-C in cMyBP-C(t3SA) myofibrils. However, the lack of increase in phosphorylation after PKA treatment suggests that these sites are not phosphorylated by PKA.
In an earlier study, Sadayappan et al19 developed a mouse expressing non–PKA-phosphorylatable cMyBP-C (MyBP-CAllP-:[t/t]) on an essentially null background resulting from the constitutive expression of a truncated variant of cMyBP-C. They observed that LV chamber diameter was dilated at diastole, septal thickness was increased, and systolic function was depressed. In the present work, we show that systolic dysfunction in the presence of a non–PKA-phosphorylatable cMyBP-C is caused by slowing of crossbridge cycling kinetics. Furthermore, we find that expression of a non–PKA-phosphorylatable cMyBP-C results in significant diastolic dysfunction in the absence of adrenergic stimulation, presumably because of slower crossbridge cycling in the absence of baseline phosphorylation of cMyBP-C. Finally, our mutant mouse exhibits substantially blunted contractile reserve in response to adrenergic stimulation as a consequence of the inability to phosphorylate cMyBP-C. There are some differences between our mouse model and the model by Sadayappan et al in terms of background genetics (KO22 versus truncation46), mutations (MyBP-CAllP-:[t/t] has additional Thr-to-Ala mutations on Thr272 and Thr28119), and expression level of mutant cMyBP-C (74% versus 40%19). Not surprisingly, echocardiography revealed some phenotypic differences between the 2 models, ie, in contrast to MyBP-CAllP-:(t/t) hearts, our cMyBP-C(t3SA) hearts showed profoundly increased LV posterior wall thickness but no LV inner chamber dilation in comparison to WT.
In conclusion, our results show that PKA phosphorylation of cMyBP-C accelerates crossbridge kinetics in myocardium and the loss of this regulatory mechanism leads to hypertrophy, diastolic dysfunction, systolic dysfunction, and reduced contractile reserve.
|
Acknowledgments |
|---|
We are grateful to Dr Hector Valdivia for help with immunofluorescence, Dr Timothy Hacker for echocardiography, and Dr J. Carter Ralphe and Peter Chen for help with the online data supplement.
Sources of Funding
Supported by NIH grant R37-HL82900 to RM.
Disclosures
None.
|
Footnotes |
|---|
Original received April 16, 2008; revision received September 2, 2008; accepted September 4, 2008.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Zipes DP, Libby P, Bonow RO, Braunwald E. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. Philadelphia, Pa: Elsevier Saunders; 2005.
2. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002; 287: 1308–1320.
3. Offer G, Moos C, Starr R. A new protein of the thick filaments of vertebrate skeletal myofibrils. Extractions, purification and characterization. J Mol Biol. 1973; 74: 653–676.[CrossRef][Medline] [Order article via Infotrieve]
4. Craig R, Offer G. The location of C-protein in rabbit skeletal muscle. Proc R Soc Lond B Biol Sci. 1976; 192: 451–461.[Medline] [Order article via Infotrieve]
5. Huxley HE, Brown W. The low-angle x-ray diagram of vertebrate striated muscle and its behaviour during contraction and rigor. J Mol Biol. 1967; 30: 383–434.[Medline] [Order article via Infotrieve]
6. Hartzell HC, Glass DB. Phosphorylation of purified cardiac muscle C-protein by purified cAMP-dependent and endogenous Ca2+-calmodulin-dependent protein kinases. J Biol Chem. 1984; 259: 15587–15596.
7. Schlender KK, Bean LJ. Phosphorylation of chicken cardiac C-protein by calcium/calmodulin-dependent protein kinase II. J Biol Chem. 1991; 266: 2811–2817.
8. Venema RC, Kuo JF. Protein kinase C-mediated phosphorylation of troponin I and C-protein in isolated myocardial cells is associated with inhibition of myofibrillar actomyosin MgATPase. J Biol Chem. 1993; 268: 2705–2711.
9. Xiao L, Zhao Q, Du Y, Yuan C, Solaro RJ, Buttrick PM. PKCepsilon increases phosphorylation of the cardiac myosin binding protein C at serine 302 both in vitro and in vivo. Biochemistry. 2007; 46: 7054–7061.[CrossRef][Medline] [Order article via Infotrieve]
10. Weisberg A, Winegrad S. Alteration of myosin cross bridges by phosphorylation of myosin-binding protein C in cardiac muscle. Proc Natl Acad Sci U S A. 1996; 93: 8999–9003.
11. Weisberg A, Winegrad S. Relation between crossbridge structure and actomyosin ATPase activity in rat heart. Circ Res. 1998; 83: 60–72.
12. Gruen M, Gautel M. Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy abolish the interaction with the regulatory domain of myosin-binding protein-C. J Mol Biol. 1999; 286: 933–949.[CrossRef][Medline] [Order article via Infotrieve]
13. Gruen M, Prinz H, Gautel M. cAPK-phosphorylation controls the interaction of the regulatory domain of cardiac myosin binding protein C with myosin-S2 in an on-off fashion. FEBS Lett. 1999; 453: 254–259.[CrossRef][Medline] [Order article via Infotrieve]
14. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003; 107: 2227–2232.
15. Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc. 2005; 80: 463–469.
16. El-Armouche A, Pohlmann L, Schlossarek S, Starbatty J, Yeh YH, Nattel S, Dobrev D, Eschenhagen T, Carrier L. Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. J Mol Cell Cardiol. 2007; 43: 223–229.[CrossRef][Medline] [Order article via Infotrieve]
17. El-Armouche A, Boknik P, Eschenhagen T, Carrier L, Knaut M, Ravens U, Dobrev D. Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation. 2006; 114: 670–680.
18. Sadayappan S, Osinska H, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, Seidman CE, Seidman JG, Robbins J. Cardiac myosin binding protein c phosphorylation is cardioprotective. Proc Natl Acad Sci U S A. 2006; 103: 16918–16923.
19. Sadayappan S, Gulick J, Osinska H, Martin LA, Hahn HS, Dorn GW, II, Klevitsky R, Seidman CE, Seidman JG, Robbins J. Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ Res. 2005; 97: 1156–1163.
20. Decker RS, Decker ML, Kulikovskaya I, Nakamura S, Lee DC, Harris K, Klocke FJ, Winegrad S. Myosin-binding protein C phosphorylation, myofibril structure, and contractile function during low-flow ischemia. Circulation. 2005; 111: 906–912.
21. Yuan C, Guo Y, Ravi R, Przyklenk K, Shilkofski N, Diez R, Cole RN, Murphy AM. Myosin binding protein C is differentially phosphorylated upon myocardial stunning in canine and rat hearts–evidence for novel phosphorylation sites. Proteomics. 2006; 6: 4176–4186.[CrossRef][Medline] [Order article via Infotrieve]
22. Harris SP, Bartley CR, Hacker TA, McDonald KS, Douglas PS, Greaser ML, Powers PA, Moss RL. Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ Res. 2002; 90: 594–601.
23. Stelzer JE, Patel JR, Moss RL. Protein kinase A-mediated acceleration of the stretch activation response in murine skinned myocardium is eliminated by ablation of cMyBP-C. Circ Res. 2006; 99: 884–890.
24. Stelzer JE, Patel JR, Walker JW, Moss RL. Differential roles of cardiac myosin-binding protein C and cardiac troponin I in the myofibrillar force responses to protein kinase A phosphorylation. Circ Res. 2007; 101: 503–511.
25. Gautel M, Zuffardi O, Freiburg A, Labeit S. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? EMBO J. 1995; 14: 1952–1960.[Medline] [Order article via Infotrieve]
26. Stelzer JE, Fitzsimons DP, Moss RL. Ablation of myosin-binding protein-C accelerates force development in mouse myocardium. Biophys J. 2006; 90: 4119–4127.[CrossRef][Medline] [Order article via Infotrieve]
27. Vincelette J, Martin-McNulty B, Vergona R, Sullivan ME, Wang YX. Reduced cardiac functional reserve in apolipoprotein E knockout mice. Transl Res. 2006; 148: 30–36.[CrossRef][Medline] [Order article via Infotrieve]
28. Wattanapermpool J, Guo X, Solaro RJ. The unique amino-terminal peptide of cardiac troponin I regulates myofibrillar activity only when it is phosphorylated. J Mol Cell Cardiol. 1995; 27: 1383–1391.[CrossRef][Medline] [Order article via Infotrieve]
29. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003; 289: 194–202.
30. Lombardi V, Piazzesi G, Ferenczi MA, Thirlwell H, Dobbie I, Irving M. Elastic distortion of myosin heads and repriming of the working stroke in muscle. Nature. 1995; 374: 553–555.[CrossRef][Medline] [Order article via Infotrieve]
31. Piazzesi G, Linari M, Reconditi M, Vanzi F, Lombardi V. Cross-bridge detachment and attachment following a step stretch imposed on active single frog muscle fibres. J Physiol. 1997; 498(pt 1): 3–15.
32. Tregear RT, Edwards RJ, Irving TC, Poole KJ, Reedy MC, Schmitz H, Towns-Andrews E, Reedy MK. X-ray diffraction indicates that active cross-bridges bind to actin target zones in insect flight muscle. Biophys J. 1998; 74: 1439–1451.[Medline] [Order article via Infotrieve]
33. Buser PT, Wu SY, Parmley WW, Jasmin G, Wikman-Coffelt J. Distinct modulation of myocardial performance, energy metabolism, and [Ca2+]i transients by positive inotropic drugs in normal and severely failing hamster hearts. Cardiovasc Drugs Ther. 1995; 9: 151–157.[CrossRef][Medline] [Order article via Infotrieve]
34. Herron TJ, Korte FS, McDonald KS. Power output is increased after phosphorylation of myofibrillar proteins in rat skinned cardiac myocytes. Circ Res. 2001; 89: 1184–1190.
35. Tong CW, Gaffin RD, Zawieja DC, Muthuchamy M. Roles of phosphorylation of myosin binding protein-C and troponin I in mouse cardiac muscle twitch dynamics. J Physiol. 2004; 558 (pt 3): 927–941.
36. Perrino C, Naga Prasad SV, Mao L, Noma T, Yan Z, Kim HS, Smithies O, Rockman HA. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest. 2006; 116: 1547–1560.[CrossRef][Medline] [Order article via Infotrieve]
37. Kentish JC, McCloskey DT, Layland J, Palmer S, Leiden JM, Martin AF, Solaro RJ. Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ Res. 2001; 88: 1059–1065.
38. Cazorla O, Szilagyi S, Vignier N, Salazar G, Kramer E, Vassort G, Carrier L, Lacampagne A. Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice. Cardiovasc Res. 2006; 69: 370–380.
39. Geeves MA, Lehrer SS. Dynamics of the muscle thin filament regulatory switch: the size of the cooperative unit. Biophys J. 1994; 67: 273–282.[Medline] [Order article via Infotrieve]
40. Moss RL, Razumova M, Fitzsimons DP. Myosin crossbridge activation of cardiac thin filaments: implications for myocardial function in health and disease. Circ Res. 2004; 94: 1290–1300.
41. Vibert P, Craig R, Lehman W. Steric-model for activation of muscle thin filaments. J Mol Biol. 1997; 266: 8–14.[CrossRef][Medline] [Order article via Infotrieve]
42. Fitzsimons DP, Patel JR, Moss RL. Cross-bridge interaction kinetics in rat myocardium are accelerated by strong binding of myosin to the thin filament. J Physiol. 2001; 530 (pt 2): 263–272.
43. Tong CW, Kolomenskii A, Lioubimov VA, Schuessler HA, Trache A, Granger HJ, Muthuchamy M. Measurements of the cross-bridge attachment/detachment process within intact sarcomeres by surface plasmon resonance. Biochemistry. 2001; 40: 13915–13924.[CrossRef][Medline] [Order article via Infotrieve]
44. Palmer BM, Georgakopoulos D, Janssen PM, Wang Y, Alpert NR, Belardi DF, Harris SP, Moss RL, Burgon PG, Seidman CE, Seidman JG, Maughan DW, Kass DA. Role of cardiac myosin binding protein C in sustaining left ventricular systolic stiffening. Circ Res. 2004; 94: 1249–1255.
45. Brickson S, Fitzsimons DP, Pereira L, Hacker T, Valdivia H, Moss RL. In vivo left ventricular functional capacity is compromised in cMyBP-C null mice. Am J Physiol Heart Circ Physiol. 2007; 292: H1747–H1754.
46. McConnell BK, Jones KA, Fatkin D, Arroyo LH, Lee RT, Aristizabal O, Turnbull DH, Georgakopoulos D, Kass D, Bond M, Niimura H, Schoen FJ, Conner D, Fischman DA, Seidman CE, Seidman JG. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest. 1999; 104: 1235–1244.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  J. F. Shaffer, R. W. Kensler, and S. P. Harris The Myosin-binding Protein C Motif Binds to F-actin in a Phosphorylation-sensitive Manner J. Biol. Chem., May 1, 2009; 284(18): 12318 - 12327. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||